

17 June 2025

Migraine Medications and Treatment

1. How many patients have been treated with the following drugs in the past four months:

- Atogepant (Aquipta) – any disease
- Erenumab (Aimovig) - any disease
- Eptinezumab (Vyepiti) – any disease
- Fremanezumab (Ajovy) - any disease
- Galcanezumab (Emgality) - any disease
- Rimegepant (Vydura) – any disease
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY

Drugs	Chronic Migraine (15+ headache days per month)	Episodic Migraine (4-15 headache days per month)
Atogepant (Aquipta)	45	
Erenumab (Aimovig)	0	
Eptinezumab (Vyepiti)	0	
Fremanezumab (Ajovy)	0	
Galcanezumab (Emgality)	34	
Rimegepant (Vydura)	n/a	5
Botulinum Toxin (i.e., Botox, Dysport, Xeomin)	105	

2. How many patients have you treated in the last four months for acute migraine with Rimegepant (Vydura)?

Nine patients have been treated in the last four months for acute migraine with Rimegepant (Vydura).

3. Does the trust actively initiate a treatment pause (usually at twelve months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?

Yes.